Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | MLNR | O43193 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10224202 | 0.89 | TRPV1 (0.53) | TRPV1GFERSMN1; SMN2HTR1DADRA1A | |
| SCHEMBL5472697 | 0.87 | TRPV1 (0.49) | TRPV1GFERMLNRHTR1DHTR1B | |
| SCHEMBL10100725 | 0.85 | DRD2 (0.53) | PARP1PARP10DRD2DRD4MLNR | |
| SCHEMBL16559644 | 0.83 | PARP10 (0.41) | TRPV1GFERSMN1; SMN2PARP1PARP10 | |
| SCHEMBL14154410 | 0.82 | SMN1; SMN2 (0.49) | TRPV1GFERSMN1; SMN2PARP1PARP10 | |
| SCHEMBL10272904 | 0.82 | SMN1; SMN2 (0.46) | TRPV1GFERSMN1; SMN2PARP1PARP10 | |
| SCHEMBL27418882 | 0.82 | MEN1 (0.44) | TRPV1MLNRALDH1A1HPGDALOX15 | |
| SCHEMBL1735429 | 0.81 | PARP10 (0.60) | GFERSMN1; SMN2PARP1PARP10DRD2 | |
| SCHEMBL30038782 | 0.81 | PARP10 (0.60) | GFERSMN1; SMN2PARP1PARP10DRD2 | |
| SCHEMBL15829267 | 0.78 | KMT2A (0.44) | TRPV1HTR1DADRA1AADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230312575-A1 | LIGANDS TO CEREBLON (CRBN) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230278993-A1 | NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-09-07 | — | — | US | disclosed |
| US-20230278993-A1 | NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-09-07 | — | — | US | disclosed |
| US-11680064-B2 | Capsid inhibitors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11661406-B2 | Method for producing intermediate useful for synthesis of SGLT inhibitor | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2023-05-30 | — | — | US | disclosed |
| US-11661406-B2 | Method for producing intermediate useful for synthesis of SGLT inhibitor | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2023-05-30 | — | — | US | disclosed |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20230026271-A1 | Piperazine Compounds for Inhibiting CPS1 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-11530219-B2 | Ligands to cereblon (CRBN) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-15 | — | — | US | disclosed |
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | NEUROGEN CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-20050075390-A1 | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6852711-B2 | Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for | AGOURON PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040106606-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2004-06-03 | — | — | US | disclosed |
| US-6528510-B1 | Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278993-A1 | NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDCD1, CD274, PDCD1LG2 | TRPV1 129/4885GFER 4146/4885SMN1; SMN2 3869/4885 |
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | PIGS, HRH4, GPR35 | TRPV1 244/4885GFER 4233/4885SMN1; SMN2 2933/4885 |
| US-20230026271-A1 | Piperazine Compounds for Inhibiting CPS1 | CPS1, CPSF1, CPSF7 | TRPV1 4178/4885GFER 3496/4885SMN1; SMN2 3905/4885 |
| US-11661406-B2 | Method for producing intermediate useful for synthesis of SGLT inhibitor | SLC5A2, SLC5A1, UGT2B7 | TRPV1 851/4885GFER 842/4885SMN1; SMN2 4413/4885 |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | TRPV1 843/4885GFER 1096/4885SMN1; SMN2 4840/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | TRPV1 73/4885GFER 1597/4885SMN1; SMN2 959/4885 |
| US-20230312575-A1 | LIGANDS TO CEREBLON (CRBN) | CRBN, CRKL, CDR2 | TRPV1 4444/4885GFER 3758/4885SMN1; SMN2 1291/4885 |
| US-11530219-B2 | Ligands to cereblon (CRBN) | CRBN, CRKL, CDR2 | TRPV1 4444/4885GFER 3758/4885SMN1; SMN2 1291/4885 |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | TRPV1 2201/4885GFER 2898/4885SMN1; SMN2 1579/4885 |
| US-20040106606-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | TRPV1 3700/4885GFER 2343/4885SMN1; SMN2 4359/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | TRPV1 327/4885GFER 962/4885SMN1; SMN2 4860/4885 |
| US-20050075390-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | TRPV1 3701/4885GFER 2409/4885SMN1; SMN2 4356/4885 |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | PIGO, GPR52, GPR88 | TRPV1 258/4885GFER 3310/4885SMN1; SMN2 3121/4885 |
| US-11680064-B2 | Capsid inhibitors for the treatment of HIV | HAVCR2, MAVS, CD4 | TRPV1 3492/4885GFER 4127/4885SMN1; SMN2 3663/4885 |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | TRPV1 244/4885GFER 3081/4885SMN1; SMN2 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.